Abstract
Neurodegenerative disorders are associated with different neurochemical and morphological alterations in the brain leading to cognitive and behavioural impairments. New therapeutic strategies comprise multifunctional drugs. The aim of the presented studies is to evaluate in vivo the novel compounds - ASS188 and ASS234 – which combine the benzylpiperidine moiety of the acetylcholinesteras (AChE) inhibitor donepezil and the indolyl propargylamino moiety of the monoaminooxidase (MAO) inhibitor, N-[(5-benzyloxy-1- methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine, with respect to their influence on cerebral amine neurotransmitters systems and neuroprotective activity. The presumed therapeutic potential of these compounds has been evaluated following their administration to rats with experimental vascular dementia. A rat model of the permanent bilateral occlusion of the common carotid arteries (BCCAO) and the holeboard memory test were employed for this purpose. Wistar rats were used, either intact or 1 day after BCCAO. ASS188 (1 mg/kg) and ASS234 (5 mg/kg) were given s.c. for 5 consecutive days. Working and reference memory in rats was evaluated by holeboard tests before- and 7 and 12 days after BCCAO. The activities of MAOs, AChE and histamine N-methyltransferase (HMT), as well as cerebral amines concentrations were assayed. A significant inhibition of brain MAO A (>95%) and weaker MAO B (ca 60%) and HMT (<30%) and reduced AChE activities were recorded with a pronounced (2 - 10 fold) increase in the cerebral concentrations of serotonin, dopamine, and noradrenaline and smaller rises (up to 30%) of histamine. The BCCAO rats treated with ASS188 or ASS234 tended to perform holeboard tests better than the BCCAO untreated group, indicating a beneficial effect of the administered therapeutics.
Keywords: Permanent bilateral occlusion of the common carotid arteries, vascular dementia, monoamine oxidases’ inhibition, brain biogenic amines’ concentration.
Current Pharmaceutical Design
Title:Effects of Novel Monoamine Oxidases and Cholinesterases Targeting Compounds on Brain Neurotransmitters and Behavior in Rat Model of Vascular Dementia
Volume: 20 Issue: 2
Author(s): Anna Stasiak, Miroslaw Mussur, Mercedes Unzeta, Abdelouahid Samadi, Jose L. Marco-Contelles and W. Agnieszka Fogel
Affiliation:
Keywords: Permanent bilateral occlusion of the common carotid arteries, vascular dementia, monoamine oxidases’ inhibition, brain biogenic amines’ concentration.
Abstract: Neurodegenerative disorders are associated with different neurochemical and morphological alterations in the brain leading to cognitive and behavioural impairments. New therapeutic strategies comprise multifunctional drugs. The aim of the presented studies is to evaluate in vivo the novel compounds - ASS188 and ASS234 – which combine the benzylpiperidine moiety of the acetylcholinesteras (AChE) inhibitor donepezil and the indolyl propargylamino moiety of the monoaminooxidase (MAO) inhibitor, N-[(5-benzyloxy-1- methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine, with respect to their influence on cerebral amine neurotransmitters systems and neuroprotective activity. The presumed therapeutic potential of these compounds has been evaluated following their administration to rats with experimental vascular dementia. A rat model of the permanent bilateral occlusion of the common carotid arteries (BCCAO) and the holeboard memory test were employed for this purpose. Wistar rats were used, either intact or 1 day after BCCAO. ASS188 (1 mg/kg) and ASS234 (5 mg/kg) were given s.c. for 5 consecutive days. Working and reference memory in rats was evaluated by holeboard tests before- and 7 and 12 days after BCCAO. The activities of MAOs, AChE and histamine N-methyltransferase (HMT), as well as cerebral amines concentrations were assayed. A significant inhibition of brain MAO A (>95%) and weaker MAO B (ca 60%) and HMT (<30%) and reduced AChE activities were recorded with a pronounced (2 - 10 fold) increase in the cerebral concentrations of serotonin, dopamine, and noradrenaline and smaller rises (up to 30%) of histamine. The BCCAO rats treated with ASS188 or ASS234 tended to perform holeboard tests better than the BCCAO untreated group, indicating a beneficial effect of the administered therapeutics.
Export Options
About this article
Cite this article as:
Stasiak Anna, Mussur Miroslaw, Unzeta Mercedes, Samadi Abdelouahid, Marco-Contelles L. Jose and Fogel Agnieszka W., Effects of Novel Monoamine Oxidases and Cholinesterases Targeting Compounds on Brain Neurotransmitters and Behavior in Rat Model of Vascular Dementia, Current Pharmaceutical Design 2014; 20 (2) . https://dx.doi.org/10.2174/13816128113199990026
DOI https://dx.doi.org/10.2174/13816128113199990026 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sleep-Wake Patterns and Cognition of Older Adults with Amnestic Mild Cognitive Impairment (aMCI): A Comparison with Cognitively Healthy Adults and Moderate Alzheimer’s Disease Patients
Current Alzheimer Research Effects of Transition Metals in the Conversion Mechanism of Prion Protein and in the Pathogenesis of Prion Diseases
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Telephone Follow-up of Older People After Hospital Admissions
Current Aging Science Association between Periodontal Health Status and Cognitive Abilitie s. The Role of Cytokine Profile and Systemic Inflammation
Current Alzheimer Research Cerebral Aneurysm Formation in Nitric Oxide Synthase-3 Knockout Mice
Current Neurovascular Research Direct and Indirect Measurement of Temporal Horn Volume and Temporal Horn Index and its Neuropsychological Correlation in Mild Cognitive Impaired and Alzheimer Diseased Patients
Current Medical Imaging Modulation of Transient Receptor Potential Vanilloid Subtype 1 (TRPV<sub>1</sub>) and Norepinephrine Transporters (NET) Protect Against Oxidative Stress, Cellular Injury, and Vascular Dementia
Current Neurovascular Research A Molecular Bridge: Connecting Type 2 Diabetes and Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Relationships Between Mitochondria and Neuroinflammation: Implications for Alzheimer’s Disease
Current Topics in Medicinal Chemistry Nanotechnology for Alzheimer Disease
Current Alzheimer Research Subject Index To Volume 12
Current Pharmaceutical Design Development of Vesicular Acetylcholine Transporter Ligands: Molecular Probes for Alzheimers Disease
Current Bioactive Compounds The Effects of Different Antioxidants on the Activity of Cerebrocortical MnSOD and Na,K-ATPase from post mortem Alzheimer’s Disease and Age-matched Normal Brains
Current Alzheimer Research Differentiating Normal from Pathological Brain Ageing Using Standard Neuropsychological Tests
Current Alzheimer Research Subject Index to Volume 1
Medicinal Chemistry Reviews - Online (Discontinued) Conference Report: 181<sup>st</sup> Annual Meeting of the American Association for the Advancement of Science (AAAS), San Jose Convention Center, San Jose, CA, USA February 12-16, 2015
CNS & Neurological Disorders - Drug Targets Cognitive Impairment in Systemic Lupus Erythematosus: Prevalence and Clinical Importance
Current Rheumatology Reviews Beneficial Neurobiological Effects of Melatonin Under Conditions of Increased Oxidative Stress
Current Medicinal Chemistry - Central Nervous System Agents Nanoparticles as a Carrier System for Drug Delivery Across Blood Brain Barrier
Current Drug Metabolism Therapeutic Potential of Janus Kinase 3 (JAK3) Inhibitors
Current Pharmaceutical Design